Tropisetron alone or in combination with dexamethasone for the prevention and treatment of emesis induced by non-cisplatin chemotherapy: a randomized trial.

2.50
Hdl Handle:
http://hdl.handle.net/10541/99239
Title:
Tropisetron alone or in combination with dexamethasone for the prevention and treatment of emesis induced by non-cisplatin chemotherapy: a randomized trial.
Authors:
Adams, M; Soukop, M; Barley, V; Yosef, H; Anderson, Heather; Boesen, E; Trask, C W; Rüfenacht, E; De Bruijn, K M
Abstract:
This study compared the efficacy and tolerability of tropisetron (Navoban, Novaban) alone or in combination with dexamethasone for the treatment of emesis induced by moderately emetogenic non-cisplatin chemotherapy. In total, 126 patients with cancer, who had never received chemotherapy and who required at least two courses of moderately emetogenic non-cisplatin chemotherapy each lasting for a minimum of 5 days, were recruited into the study. Patients were randomized to receive tropisetron, 5 mg o.d., plus either dexamethasone, 12 mg i.v. on day 1 followed by 4 mg orally b.i.d. on days 2-5, or placebo. Greater control of acute and delayed vomiting and nausea was achieved in patients given the tropisetron-dexamethasone combination than in those who received the tropisetron-placebo treatment. The majority of adverse events were mild and could be attributed to the chemotherapeutic regimen used or to the underlying disease. Patients and investigators both rated tropisetron alone or in combination with dexamethasone as a highly effective and well-tolerated antiemetic treatment. The results of this study show that tropisetron, 5 mg o.d., is an effective, well-tolerated and simple to use antiemetic treatment for patients receiving moderately emetogenic non-cisplatin chemotherapy. The addition of dexamethasone increases the efficacy of tropisetron without significantly decreasing its tolerability.
Affiliation:
Velindre Hospital, Whitchurch, Cardiff, UK.
Citation:
Tropisetron alone or in combination with dexamethasone for the prevention and treatment of emesis induced by non-cisplatin chemotherapy: a randomized trial. 1995, 6 (4):514-21 Anticancer Drugs
Journal:
Anti-Cancer Drugs
Issue Date:
Aug-1995
URI:
http://hdl.handle.net/10541/99239
PubMed ID:
7579555
Type:
Article
Language:
en
ISSN:
0959-4973
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorAdams, Men
dc.contributor.authorSoukop, Men
dc.contributor.authorBarley, Ven
dc.contributor.authorYosef, Hen
dc.contributor.authorAnderson, Heatheren
dc.contributor.authorBoesen, Een
dc.contributor.authorTrask, C Wen
dc.contributor.authorRüfenacht, Een
dc.contributor.authorDe Bruijn, K Men
dc.date.accessioned2010-05-19T10:15:08Z-
dc.date.available2010-05-19T10:15:08Z-
dc.date.issued1995-08-
dc.identifier.citationTropisetron alone or in combination with dexamethasone for the prevention and treatment of emesis induced by non-cisplatin chemotherapy: a randomized trial. 1995, 6 (4):514-21 Anticancer Drugsen
dc.identifier.issn0959-4973-
dc.identifier.pmid7579555-
dc.identifier.urihttp://hdl.handle.net/10541/99239-
dc.description.abstractThis study compared the efficacy and tolerability of tropisetron (Navoban, Novaban) alone or in combination with dexamethasone for the treatment of emesis induced by moderately emetogenic non-cisplatin chemotherapy. In total, 126 patients with cancer, who had never received chemotherapy and who required at least two courses of moderately emetogenic non-cisplatin chemotherapy each lasting for a minimum of 5 days, were recruited into the study. Patients were randomized to receive tropisetron, 5 mg o.d., plus either dexamethasone, 12 mg i.v. on day 1 followed by 4 mg orally b.i.d. on days 2-5, or placebo. Greater control of acute and delayed vomiting and nausea was achieved in patients given the tropisetron-dexamethasone combination than in those who received the tropisetron-placebo treatment. The majority of adverse events were mild and could be attributed to the chemotherapeutic regimen used or to the underlying disease. Patients and investigators both rated tropisetron alone or in combination with dexamethasone as a highly effective and well-tolerated antiemetic treatment. The results of this study show that tropisetron, 5 mg o.d., is an effective, well-tolerated and simple to use antiemetic treatment for patients receiving moderately emetogenic non-cisplatin chemotherapy. The addition of dexamethasone increases the efficacy of tropisetron without significantly decreasing its tolerability.en
dc.language.isoenen
dc.subjectCanceren
dc.subject.meshAntiemetics-
dc.subject.meshAntineoplastic Agents-
dc.subject.meshDexamethasone-
dc.subject.meshDouble-Blind Method-
dc.subject.meshDrug Combinations-
dc.subject.meshFemale-
dc.subject.meshHumans-
dc.subject.meshIndoles-
dc.subject.meshMale-
dc.subject.meshMiddle Aged-
dc.subject.meshNausea-
dc.subject.meshNeoplasms-
dc.subject.meshVomiting-
dc.titleTropisetron alone or in combination with dexamethasone for the prevention and treatment of emesis induced by non-cisplatin chemotherapy: a randomized trial.en
dc.typeArticleen
dc.contributor.departmentVelindre Hospital, Whitchurch, Cardiff, UK.en
dc.identifier.journalAnti-Cancer Drugsen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.